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Abstract
Parallel randomized trial (RT) and real-world (RW) data are becoming increasingly avail-
able for treatment evaluation. Given the complementary features of the RT and RW data,
we propose an elastic integrative analysis of the RT and RW data for accurate and robust es-
timation of the heterogeneity of treatment effect (HTE), which lies at the heart of precision
medicine. When the RW data are not subject to unmeasured confounding, our approach
combines the RT and RW data for optimal estimation by exploiting the semiparametric
efficiency theory. The proposed approach also automatically detects the existence of unmea-
sured confounding in the RW data and gears to the RT data. Utilizing the design advantage
of RTs, we are able to gauge the reliability of the RW data and decide whether or not to
use RW data in an integrative analysis. The advantage of the proposed research lies in in-
tegrating the RT and big RW data seamlessly for consistent HTE estimation. We apply the
proposed method to characterize who can benefit from adjuvant chemotherapy in patients
with stage IB non-small cell lung cancer.
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1 INTRODUCTION
Because of patient heterogeneity in response to various aspects of treatment, the paradigm of
biomedical and health policy research is shifting from the “one-size-fits-all” treatment approach
to precision medicine (Hamburg and Collins, 2010). Toward that end, an important step is to
understand how treatment effect varies across patient characteristics, known as heterogeneity of
treatment effect (HTE) (Rothwell, 2005b, Rothwell et al., 2005). Randomized trials (RTs) are
the gold standard method for treatment effect evaluation, because randomization of treatment
ensures that treatment groups are comparable and biases are minimized to the extent possible.
However, due to eligibility criteria for recruiting patients, the RT sample is often limited in patient
diversity, which renders the trial under-powered to estimate the HTE. On the other hand, big
RW data are increasingly available for research purposes, such as electronic health records, claims
databases, and disease registries, that have much broader demographic and diversity compared
to RT cohorts. Recently, several national organizations (Norris et al., 2010) and regulatory
agencies (Sherman et al., 2016) have advocated using RW data to have a faster and less costly
drug discovery process. Indeed, big data provide unprecedented opportunities for new scientific
discovery; however, they also present challenges such as confounding due to lack of randomization.
The motivating application is to evaluate adjuvant chemotherapy for resected non-small cell
lung cancer (NSCLC) at early-stage disease. Adjuvant chemotherapy for resected NSCLC has
been shown to be effective in late-stage II and IIIA disease on the basis of RTs (Le Chevalier,
2003). However, the benefit of adjuvant chemotherapy in stage IB NSCLC disease is unclear.
Cancer and Leukemia Group B (CALGB) 9633 is the only RT designed specifically for stage IB
NSCLC (Strauss et al., 2008); however, it comprises only 330 patients which was undersized to
detect clinically meaningful improvements for adjuvant chemotherapy. “Who can benefit from
adjuvant chemotherapy with stage IB NSCLC?” remains an important clinical question. An
exploratory analysis of CALGB 9633 showed that patients with tumor size ≥ 4.0 cm in diameter
may benefit from adjuvant chemotherapy (Strauss et al., 2008). This benefit was also found in an
analysis of a dataset from the National Cancer Database (NCDB) (Speicher et al., 2015), while
an analysis based on the Surveillance, Epidemiology, and End Results (SEER) database found
adjuvant chemotherapy extended survivals as compared to observation in all tumor size groups
(Morgensztern et al., 2016). Although such population-based disease registries provide rich
information citing the real-world usage of adjuvant chemotherapy, the concern is the confounding
bias associated with RW data. Our goal is to integrate the CALGB 9633 trial with data from
the NCDB to improve the RT findings regarding the HTE of adjuvant chemotherapy with both
age and tumor size.
Many authors have proposed methods for generalizing the average treatment effects (ATEs)
from RTs to the target population, whose covariate distribution can be characterized by the RW
data (Rothwell, 2005a, Cole and Stuart, 2010, Stuart et al., 2011, Hernan and VanderWeele,
2011, Pearl and Bareinboim, 2011, Tipton, 2013, O’Muircheartaigh and Hedges, 2014, Stuart
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et al., 2015, Keiding and Louis, 2016, Rudolph and van der Laan, 2017, Buchanan et al., 2018).
When both RT and RW data provide covariate, treatment and outcome information, there are
two main approaches for integrative analysis: meta analysis (e.g., Verde and Ohmann, 2015)
and pooled patient data analysis. The major drawback of meta analysis is that it uses only
aggregated information and does not distinguish the roles of the RT and RW data, which have
unique strengths and weaknesses. The second approach includes all patients, but pooling of the
data from two sources breaks the randomization of treatments and therefore relies on causal
inference methods to adjust for confounding bias (e.g., Prentice et al., 2005, 2006). Importantly,
we cannot rule out possible unmeasured confounding in the RW data. Moreover, all existing
methods focused mainly on ATEs but not on HTEs, which lie at the heart of precision medicine.
To acknowledge the advantages from the RT and RW data, we propose an elastic algorithm of
combining the RT and RW data for accurate and robust estimation of the HTE. When desirable
assumptions required for an integrative analysis of the RT and RW data are met, we use the
semiparametric efficiency theory (Begun et al., 1983, Newey, 1990, Bickel et al., 1993, Robins,
1994) for estimating the HTE. The main identification assumptions underpinning our method
are (i) transportability of the HTE from the RT and RW data to the target population and (ii) no
unmeasured confounding in the RW data. Assumptions (i) and (ii) plus the HTE function consti-
tute a semiparametric model for the data. We focus on the semiparametric efficient estimator of
the HTE, which attains the semiparametric efficiency bound. To improve the robustness against
parametric model misspecification, we consider double machine learning methods, which allow
flexible models for two nuisance functions namely the propensity score and the outcome mean
function. We provide conditions under which the optimal HTE estimator retains the parametric
rate consistency.
We also consider the case when the RW data may violate the no unmeasured confounding
assumption. Utilizing the design advantage of RTs, we derive a test statistic to gauge the relia-
bility of the RW data and decide whether or not to use the RW data in an integrative analysis.
We propose an elastic test-based integrative estimator that uses the optimal combining rule
for estimation if the violation test is not significant and retains only the RT counterpart if the
violation test is significant. This guarantees consistent estimation of the HTE. The resulting
estimator is non-regular due to the non-smooth indicator function of the violation test. Con-
sequently, we show that the nonparametric bootstrap inference is inconsistent. To mitigate the
non-regularity, we propose a soft-thresholding method, so that the resulting elastic integrative
estimator is smooth and the bootstrap can be implemented for inference.
This article is organized as follows. Section 2 introduces the basic setup, the HTE, the
identification assumptions and semiparametric efficiency score for parameter estimation. Section
3 develops locally adaptive estimators including the doubly robust estimator using parametric
models for nuisance functions and the double machine learning estimator using flexible machine
learning models for nuisance functions. Section 4 establishes a test statistic for gauging the
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reliability of the RE data, an elastic test-based HTE estimator, and their asymptotic properties.
Section 5 presents a simulation study to evaluate the performance of the proposed estimator
in terms of efficiency and robustness. Section 6 applies the proposed method to a combined
database of RT and RW data to characterize the HTE of adjuvant chemotherapy in patients
with stage IB non-small cell lung cancer. We relegate technical details and all proofs to the
supplementary material.
2 BASIC SETUP
2.1 Notation, the HTE, and two data sources
Let X be a vector of pre-treatment covariates with the first component being 1, A ∈ {0, 1}
be the binary treatment, and Y be the outcome of interest. To fix ideas, we consider Y to
be continuous or binary, although our framework can be extended to general-type outcomes
including the survival outcome. We use potential outcomes (Neyman, 1923, Rubin, 1974) to
define causal effects. Under the Stable Unit of Treatment Value assumption, let Y (a) be the
potential outcome had the subject been given treatment a, for a = 0, 1. By the causal consistency
assumption, the observed outcome is Y = Y (A) = AY (1) + (1−A)Y (0).
Based on the potential outcome, the individual treatment effect is Y (1) − Y (0) and the
heterogeneous treatment effect can be characterized through τ(X) = E[Y (1) − Y (0) | X]. We
assume the HTE function to be
τ(X) = τψ0(X) = E[Y (1)− Y (0) | X;ψ0], (1)
where ψ0 ∈ Rp is a vector of unknown parameters. For a binary outcome, τ(X) is also called
the causal risk difference. Alternative causal estimands may also be considered, such as causal
relative risk.
Importantly, τψ0(X) has applications in precision medicine for the discovery of optimal treat-
ment regimes that are tailored to individual’s characteristics (Chakraborty and Moodie, 2013).
The parametric family of HTEs is interpretable and desirable in clinical settings.
We illustrate the HTE function in the following examples.
Example 1 For a continuous outcome, a linear HTE function is τψ0(X) = XTψ0, where each
component of ψ0 quantifies the magnitude of the treatment effect of each X.
Example 1 has been considered in Tian et al. (2014) and Shi et al. (2016).
Example 2 For a binary outcome, an HTE function for the causal risk difference is τψ0(X) =
{exp(XTψ0)− 1}/{exp(XTψ0) + 1}.
Example 2 has been considered in Tian et al. (2014) and Richardson et al. (2017).
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To evaluate adjuvant chemotherapy, let Y be the indication of cancer recurrence within 1
year of surgery, and let X include age and tumor size. This model entails that, on average,
the treatment would increase or decrease the risk of cancer recurrence had the patient received
adjuvant chemotherapy by |τψ0(X)|, and the magnitude of increase depends on age and tumor
size. If X>ψ0 < 0, it indicates that the treatment is beneficial for this patient. Moreover, if
ψ0,1 < 0 and ψ0,2 < 0, then older patients with larger tumor sizes would have greater benefit
from adjuvant chemotherapy.
The target population of size N consists of all patients with certain diseases where the new
treatment is intended to be given. We consider two data sources: one from the RT study and
the other from the RW study. Let δ = 1 denote RT participation, and let δ = 0 denote RW
participation. The RT data consist of {(Ai, Xi, Yi, δi = 1) : i ∈ A} with sample size n, and the
RW data consist of {(Ai, Xi, Yi, δi = 0) : i ∈ B} with sample size m, where A and B are sample
index sets for the two data sources.
2.2 Identification of the HTE from the RT and RW data
We first consider an idealistic situation where the HTE can be identified from both the RT and
RW data. In order to achieve identification, X must be sufficiently rich to capture treatment
effect heterogeneity and also eliminate confounding bias. We formalize these conditions as follows.
Assumption 1 (i) E[Y (1)− Y (0) | X, δ] = τ(X), and (ii) Y (a)⊥ A | (X, δ) for δ ∈ {0, 1} and
a ∈ {0, 1}, where ⊥ denotes “is independent of” (Dawid, 1979).
Assumption 1 (i) states that the HTE functions from the RT and RW samples are the same
as the HTE function from the target population. Assumption 1 (ii) entails that the treatment
assignment mechanisms in the RT and the RW study follow randomization mechanisms based
on the pre-treatment variables X. By the trial design, we assume that Assumption 1 holds
for the RT data (δ = 1) throughout the paper. We regard Assumption 1 for the RW data
(δ = 0) to be an idealistic assumption, which may be violated. If Assumption 1 holds, we
will consider a semiparametric efficient strategy that combines both data sources for optimal
estimation. However, if Assumption 1 is violated for the RW data, our proposed method will
automatically detect the violation and retain only the RT data for estimation.
We define
Hψ = Y − τψ(X)A. (2)
Intuitively, Hψ0 subtracts from the subject’s observed outcome Y the treatment effect of the
subject’s observed treatment τψ0(X)A, so it is mimicking the potential outcome under the control
treatment Y (0). Formally, we show in the supplementary material that E[Hψ0 | A,X, δ] =
E[Y (0) | A,X, δ]. Therefore, by Assumption 1,
E[Hψ0 | A,X, δ] = E[Hψ0 | X, δ]. (3)
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2.3 The semiparametric efficient score
Model (1) and Restriction (3) constitute the semiparametric model. Here, the parameter of pri-
mary interest is ψ0, encoding the treatment effect, and other parameters, such as the unspecified
distribution, are nuisance. Suppose further that E
[
H2ψ0 | A,X, δ
]
= E
[
H2ψ0 | X, δ
]
, then the
semiparametric efficient score of ψ0 (Robins, 1994) is
Seff,ψ0(V ) =
{
∂τψ0(X)
∂ψ
}
{A− P (A = 1 | X, δ)}{V[Hψ0 | X, δ]}−1 (Hψ0 − E[Hψ0 | X, δ]) . (4)
We provide examples to elucidate the semiparametric efficient score below.
Example 3 For the continuous outcome, suppose that the treatment effect model (1) is correctly
specified as in Example 1. The semiparametric efficient score of ψ0 is
Seff,ψ0(V ) = X{A− P (A = 1 | X, δ)}(V[Hψ0 | X, δ])−1 (Hψ0 − E[Hψ0 | X, δ]) .
For the binary outcome, suppose that the treatment effect model (1) is correctly specified as
in Example 2. The semiparametric efficient score of ψ0 is
Seff,ψ0(V ) = X
2 exp(XTψ0)
{exp(XTψ0) + 1}2 {A− P (A = 1 | X, δ)}
× {E[Hψ0 | X, δ](1− E[Hψ0 | X, δ])}−1 (Hψ0 − E[Hψ0 | X, δ]) .
3 LOCALLY ADAPTIVE ESTIMATION
3.1 Double robust estimation
In principle, the semiparametric efficient estimator ψ̂ for ψ0 can be obtained by solving PNSeff,ψ =
0, and attains the semiparametric variance bound under the semiparametric model (3). However,
Seff,ψ depends on the true unknown distribution through P (A = 1 | X, δ), E[Hψ0 | X, δ], and
V(Hψ0 | X, δ), and thus solving PNSeff,ψ = 0 is infeasible. In order to obtain a feasible estimator
with good efficiency properties, we consider approximating the unknown functions with estima-
tors of them under some working models. For ease of computation, one can take V[Hψ0 | X, δ] to
be an identity matrix for a continuous outcome as commonly done in the generalized estimating
equation literature. We assume that
E[Hψ0 | X, δ] = E[H | X, δ; η0], (5)
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which is known up to a finite-dimensional parameter η0. In the RT, the propensity score is known
by design. Without loss of generality, we assume P (A = 1 | X, δ = 1) = 0.5. However, in the
RW data, the propensity score is unknown. We assume a parametric propensity score model as
P (A = 1 | X, δ = 0) = P (A = 1 | X, δ = 0;α0), (6)
which is known up to a finite-dimensional parameter α0.
We propose the following locally adaptive algorithm for estimating ψ0:
Step 1. Posit a parametric model P (A = 1 | X, δ = 0;α0) with the unknown parameter α0, e.g.,
a logistic regression model, and obtain α̂ based on {(Ai, Xi, δi = 0) : i ∈ B}.
Step 2. Obtain a preliminary estimator ψ̂p by solving
∑
i∈A[{Ai−P (A = 1 | Xi, δi = 1)}Hψ,i] =
0.
Step 3. Posit a parametric model E[Hψ0 | X, δ; η0] with the unknown parameter η0, and obtain
η̂ based on {(Ai, Xi, Hψ̂p,i, δi) : i ∈ A ∪ B}.
Step 4. Let Seff,ψ(V ; α̂, η̂) be Seff,ψ(V ) with the unknown quantities replaced by the estimated
parametric models in Steps 1–3. We obtain the estimator ψ̂eff by solving the estimating
equation for ψ: ∑
i∈A∪B
Seff,ψ(Vi; α̂, η̂) = 0. (7)
Proposition 1 (Double robustness) Suppose Assumption 1 holds. Under the treatment effect
model τψ0(X), the estimator ψ̂eff solving (7) is doubly robust in the sense that the estimating
function remains unbiased if either model (5) or model (6) is correctly specified, but not necessarily
both.
3.2 Double machine learning estimation
The doubly robust estimators are initially developed to gain robustness to parametric misspecifi-
cation but are now known to be robust to approximation errors using machine learning methods;
see, e.g., Farrell (2015) and Chernozhukov et al. (2018). This new doubly robust feature is mainly
investigated in the context of estimating the average treatment effect. We will investigate this
feature for estimating the HTE.
Based on the semiparametric efficient score (4), we propose to use flexible machine learning
methods for estimating P (A = 1 | X, δ = 0) and E[Hψ0 | X, δ]. This allows alleviating bias
from misspecification of parametric models. Let P (A = 1 | X, δ = 0; α̂) and E[Hψ0 | X, δ; η̂]
be general approximations for P (A = 1 | X, δ = 0) and E[Hψ0 | X, δ] respectively. The double
machine learning HTE estimator ψ̂eff(ml) solves (7) with the general machine learning estimators
of two nuisance functions.
We provide regularity conditions that ensure ψ̂eff(ml) retains root-m consistent.
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Theorem 1 Suppose Assumption 1 and the following regularity conditions hold:
Condition 1 ‖P (A = 1 | X, δ = 0; α̂) − P (A = 1 | X, δ = 0)‖ = oP(1) and ‖E[Hψ0 | X, δ; η̂] −
E[Hψ0 | X, δ]‖ = oP(1);
Condition 2 ‖P (A = 1 | X, δ = 0; α̂) − P (A = 1 | X, δ = 0)‖ × ‖E[Hψ0 | X, δ; η̂] − E[Hψ0 |
X, δ]‖ = oP(m−1/2).
Then ψ̂eff(ml) is root-m consistent for ψ0, and its variance achieves the semiparametric effi-
ciency bound.
As a concrete example, we approximate both nuisance functions by the method of sieves.
For simplicity, we consider the power series; however, our discussion extends to general sieve
basis functions such as Fourier series, splines, wavelets, and artificial neural networks (see, e.g.,
Chen, 2007). Let dX be the dimension of X. For a dX -vector of non-negative integers κ =
(κ1, . . . , κdX ), let |κ| =
∑dX
l=1 κl and X
κ =
∏dX
l=1X
κl
l . Define a series {κ(k) : k = 1, 2, . . .} for all
distinct vectors of κ such that |κ(k)| ≤ |κ(k + 1)|. Based on this series, we consider a K-vector
g(X) = {g1(X), . . . , gK(X)}> = {Xκ(1), . . . , Xκ(K)}>.
To accommodate different type of variables, we approximate P (A = 1 | X, δ = 0) and
E[Hψ0 | X, δ] by the generalized sieves functions
logitP (A = 1 | X, δ = 0;α∗) = α∗>g(X), (8)
h (E[Hψ0 | X, δ]) = ηδ∗>g(X), (9)
where h(·) is a link function, e.g., for a continuous outcome, h(·) is an identity link function, and
for a binary outcome, h(·) is a logit link function, and
α∗ = arg min
α
E[P (A = 1 | X, δ = 0)− expit{α>g(X)}]2,
ηδ∗ = arg min
η
E
(
E[Hψ0 | X, δ]− h−1{ηδ>g(X)}
)2
.
We replace Steps 1 and 3 in the locally adaptive estimation algorithm in Section 3 by the
following steps.
Step DML-1. Approximate logitP (A = 1 | X, δ = 0) by (8), where α = (α1, . . . , αK). Obtain
α̂ by fitting the approximate sieve model based on {(Ai, Xi, δi = 0) : i ∈ B}.
Step DML-3. Approximate E[Hψ0 | X, δ] by (9). Let ηT = (ηTrt, ηTrw), where ηTrt = (η11, . . . , η1K)
and ηTrw = (η01, . . . , η0K). Obtain η̂
T = (η̂Trt, η̂
T
rw) by fitting the approximate sieve function
based on {(Ai, Xi, Hψ̂p,i, δi) : i ∈ A ∪ B}.
Under the regularity conditions specified in the supplementary material, the sieves estimators
satisfy the conditions in Theorem 1 and therefore ψ̂eff(ml) is root-m consistent and semiparametric
efficient.
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4 ELASTIC INTEGRATION OF THE RW DATA
A major concern for integrating the RT and RW data lies in the possibly poor quality of the RW
data. If the RW data did not capture all confounding variables, Assumption 1 may be violated.
Then, combining the RC and RW data into an integrative analysis would lead to a biased HTE
estimator. Therefore, it is critical to gauge the reliability of the RW analysis.
4.1 Detection of the violation of Assumption 1 in RW
For simplicity of exposition, we now denote the semiparametric efficient score based solely on
the RT or RW data as Srt,ψ(V ;α, η) = δSψ(V ;α, η) and Srw,ψ(V ;α, η) = (1 − δ)Sψ(V ;α, η),
respectively. We obtain an initial estimator ψ̂rt by solving the estimating equation based solely
on the RT data,
∑
i∈A Srt,ψ(Vi;α0, η̂rt) = 0. It is important to note that the propensity score
in the RT, P (A = 1 | X, δ = 1), is known by design. Therefore, by the double robustness
property, ψ̂rt is always consistent, regardless of whether or not the outcome mean model is
correctly specified. If Assumption 1 holds for the RW data, Srw,ψ0(V ;α0, η0) is unbiased. If
Assumption 1 is violated, Srw,ψ0(V ;α0, η0) is no longer unbiased. Based on this key insight, to
detect the violation of Assumption 1 for using the RW data, we construct the test statistic
T =
{∑
i∈B
S
rw,ψ̂rt
(Vi; α̂, η̂rw)
}T
Σ̂−1SS
{∑
i∈B
S
rw,ψ̂rt
(Vi; α̂, η̂rw)
}
, (10)
where Σ̂SS is a consistent variance estimator for
∑
i∈B Srw,ψ̂rt(Vi; α̂, η̂rw), e.g., obtained by the
bootstrap or re-sampling method.
To investigate the statistical property of the test statistic, we make the following regularity
conditions. We use An
·∼ Bn to denote that the two random variables An and Bn have the same
asymptotic distribution as n→∞. For a vector A, let A⊗2 denote AAT.
Assumption 2 The following regularity conditions hold:
(i) mn−1 → ρ <∞;
(ii) Let pirt(V ) = P (δ = 1 | V ), Γrt = E[pirt(V )∂Sψ0(V ;α0, η0)/∂ψ] <∞ and Γrw = E[∂Sψ0(V ;α0, η0)/∂ψ] <
∞. We have that Γrt and Γrw are invertible;
(iii) Let Zrt ∼ N (0, Vrt) and Zrw ∼ N (0, Vrw), where Vrt = E[pirt(V )Seff,ψ0(V ;α0, η0)⊗2] < ∞
and Vrw = E[Seff,ψ0(V ;α0, η0)⊗2] <∞. We have
n−1/2
∑
i∈A
Srt,ψ0(Vi;α0, η0)
·∼ Zrt,
m−1/2
∑
i∈B
Srw,ψ0(Vi;α0, η0)
·∼ Zrw.
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Assumption 2 (i) is a convenient condition to simplify the exposition of the theoretical results.
Assumption 2 (ii) and (iii) are standard in the M-estimation literature.
Theorem 2 serves as the basis for detecting the violation of assumption in the RW data.
Theorem 2 Under Assumptions 1, 2, and assumptions in Theorem 1,
T
·∼ (Zrw + ΓTZrt)Σ−1SS(Zrw + ΓTZrt) ∼ χ2p,
a Chi-square distribution with degrees of freedom p, where p is the dimension of ψ0, ΓT =
ΓTrw(Γ
T
rt)
−1ρ1/2, ΣSS = Vrw + ΓTVrtΓ, Zrw, Zrt, Γrw, and Γrt are defined in Assumption 2.
The construction of T depends on a consistent variance estimator Σ̂SS .
Step B-1. Obtain a bootstrap RT sample A∗. Obtain a bootstrap replicate of η̂rt, η̂∗rt, by
fitting the generalized sieves function in Step DML-3 based on {(Ai, Xi, Hψ̂p,i, δi = 1) :
i ∈ A∗}. Obtain a bootstrap replicate of ψ̂rt, ψ̂∗rt, by solving the estimating equation∑
i∈A∗ Srt,ψ(Vi;α0, η̂
∗
rt) = 0.
Step B-2. Obtain a bootstrap RW sample B∗. Obtain a bootstrap replicate of (α̂, η̂rw) as
(α̂∗, η̂∗rw) by fitting the generalized sieves functions in Step DML-1 and Step DML-3. Obtain
replicates α̂∗ and η̂∗rw based on B∗. Obtain a bootstrap replicate of
∑
i∈B Srw,ψ̂rt(Vi; α̂, η̂rw)
as
∑
i∈B∗ Srw,ψ̂∗rt(Vi; α̂
∗, η̂∗rw).
Step B-3. Repeat Steps B-1 and B-2 for a large number of times. Calculate the bootstrap
variance estimator Σ̂SS as the empirical variance of
∑
i∈B∗ Srw,ψ̂∗rt(Vi; α̂
∗, η̂∗rw) over a large
number of bootstrap replicates.
Remark 1 In Steps B-1 and B-2, instead of generating bootstrap resamples, we can use the
original RT and RW samples with bootstrap replication weights. That is, for i ∈ A, we obtain the
bootstrap replication weights ω∗i = n
−1n∗i with (n
∗
i : i ∈ A) following a multinomial random vector
with n draws on n equal probability cells, and for i ∈ B, we obtain the bootstrap replication weights
ω∗i = m
−1m∗i with (m
∗
i : i ∈ B) following a multinomial random vector with m draws on m equal
probability cells. More generally, we can use the replication weights that satisfy E[ω∗i | obs] = 1,
E[ω∗2i | obs] = 1, and E[ω∗4i | obs] <∞, where ’obs’ denotes the observed data. For example, one
can generate the ω∗i ’s from Exp(1) independently from the observed data.
4.2 Elastic integration
Let cγ = χ2p,γ be the (1− γ)th percentile of χ2p. By Theorem 2, for a small γ, if T ≥ cγ , there is
a strong evidence to reject Assumption 1 for the RW data; i.e., there is a detectable bias for the
RW data estimator. In this case, we would only use the RT data for estimation. On the other
hand, if T < cγ , there is no strong evidence for the bias of the RW data estimator, and therefore,
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we would combine both the RT and RW data for optimal estimation. Our strategy leads to the
estimating equation for ψ0 given by∑
i∈A∪B
{δiSψ(Vi; α̂, η̂rt) + I(T < cγ)(1− δi)Sψ(Vi; α̂, η̂rw)} = 0. (11)
We propose the elastic integrative estimator ψ̂elas solving (11).
Let
Γelas = E
[
ρ−1δ
∂Sψ0(V ;α0, η0)
∂ψ
+ I(T < cγ)
∂Sψ0(V ;α0, η0)
∂ψ
]
.
The following theorem establishes the statistical properties.
Theorem 3 Under Assumption 2 and assumptions in Theorem 1, the elastic integrative estima-
tor ψ̂elas solving (11) is consistent for ψ0.
If Assumption 1 holds, m1/2(ψ̂elas−ψ0) has a limiting mixing distribution; that is a conditional
distribution as
{−(ΓTelasρ1/2)−1(Zrt + ρ1/2Zrw) | T < cγ} with probability 1− γ and a conditional
distribution as
{−(ΓTelasρ1/2)−1Zrt | T ≥ cγ} with probability γ.
If Assumption 1 is violated, m1/2(ψ̂elas−ψ0) has a limiting normal distribution as −(ΓTelasρ1/2)−1Zrt.
A challenge arises for inference, because the indicator function in (11) renders a non-regular
estimator of ψ0. We show that the nonparametric bootstrap is inconsistent.
Theorem 4 Let ψ̂∗elas be the nonparametric bootstrap replicate of ψ̂elas. Under Assumption 2
and assumptions in Theorem 1, the bootstrap distribution of m1/2(ψ̂∗elas− ψ̂elas) give the observed
data is inconsistent for the distribution of m1/2(ψ̂elas − ψ0).
To address this issue, we may use the m-out-of-n bootstrap (Shao, 1994, Bickel et al., 1997)
or subsampling (Politis et al., 1999) for conducting valid statistical inference for non-regular
estimators. These procedures, however, rely on good choices of the subsample size. Laber and
Murphy (2011) proposed an adaptive confidence interval for the test error in classification, a non-
regular statistics, by bootstrapping the upper and lower bounds of the test error; however, its
computation burden is heavy and also the adaptive confidence intervals are often conservation.
To avoid this complication, instead of using the indicator function to make a binary decision
to include or exclude the RW data from analysis, similar to Yang and Ding (2018), we propose
to use a smooth weight function Φ (cγ − T ) to replace I(T < cγ), where Φ(z) is the normal
cumulative distribution with zero mean and variance 2. The proposed estimator ψ̂ solves [c]∑
i∈A∪B
{δiSψ(Vi; α̂, η̂) + Φ (cγ − T ) (1− δi)Sψ(Vi; α̂, η̂)} = 0. (12)
As  → 0, the smooth weight function Φ (cγ − T ) converges to I(T < cγ). Using the smooth
weight function mitigates the non-regularity of the estimator ψ̂ solving (11). We suggest using
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the percentile bootstrap confidence interval (CI). Let ψ̂∗ be the bootstrap replicates. The 100(1−
α)% percentile bootstrap CI is (ψ̂∗,1−α/2, ψ̂
∗
,α/2), where ψ̂
∗
,p is the pth percentile of the ψ̂∗ ’s.
Remark 2 An important issue regarding the proposed elastic integrative estimator is the choice
of cγ and , which involves a efficiency-robustness trade-off. On the one hand, if cγ becomes
larger, it becomes less likely that the bias from the RW data can be detected, and therefore the
elastic integrative estimator is more susceptible to the confounding bias or the bias due to model
misspecification. On the other hand, if cγ becomes close to zero, then the proposed integrative
estimator becomes the RT estimator and therefore gains robustness. In practice, the investigator
should decide the choice of cγ based on the study and the data given at hand. For , we recommend
a sensitivity analysis varying  over a grid, for example, 1, 2, etc. With the choices of  leading
to similar point estimation of ψ̂, a larger value of  reduces the non-regularity to a larger extent
and then the percentile bootstrap CI has the coverage rate closer to the nominal rate.
5 SIMULATION
In this section, we evaluate the finite sample performance of the proposed elastic estimator
via a set of simulation experiments for robustness against parametric model assumptions and
assumption violations.
5.1 Robustness against parametric model assumptions
We first generate a target population of size N = 105. We generate the covariate X =
(1, X1, X2)
T, where Xj ∼ N (0, 1) for each j = 1, 2. Let Z = (1, Z1, Z2, Z3, Z4) be the non-
linear transformation of X, where Z1 = exp(X1/3), Z2 = X2/{1 + exp(X1)}, Z3 = X1X2,
Z4 = X1 +X2, and each Zj is standardized so that E(Zj) = 0 and var(Zj) = 1.
For the continuous outcome, we consider both the linear and nonlinear potential outcome
models:
OM-c I: Y (a)|X = βT0X + a · ψT0X + (a), where β0 = (0, 1, 1)T, ψ0 = (1, 1, 1)T, and (a) ∼
N (0, 1), for a = 0, 1,
OM-c II: Y (a)|X = βT0Z + a · ψT0X + (a), where β0 = (1, 1, 1, 1, 1)T, ψ0 = (1, 1, 1)T, and
(a) ∼ N (0, 1), for a = 0, 1.
For binary outcomes, we generate potential outcome according to
OM-b I: Y (a)|X ∼ Bernoulli{µ(a,X)}, where logit{µ(a,X)} = (2a − 1) · (ψT0X), where ψ0 =
0.5(1, 1, 1)T, for a = 0, 1,
12
OM-b II: Y (a)|X ∼ Bernoulli{µ(a,X)}, for a = 0, 1, where
µ(0, X) =
eφ(X){2− τψ0(X)}+ τψ0(X)
2{eφ(X) − 1}
−
√[
eφ(X){τψ0(X)− 2} − τψ0(X)
]2
+ 4eφ(X){1− τψ0(X)}(1− eφ(X))
2{eφ(X) − 1} ,
µ(1, X) = µ(0, X) + τψ0(X), φ(X) = (0, 1,−1)X, τψ0(X) = tanh(0.5ψT0X), and ψ0 =
0.5(1, 1, 1)T. Then, µ(a,X) ∈ [0, 1] for a = 0, 1 (Richardson et al., 2017).
We generate the indicator of selection into the RT sample according to δ | X ∼ Bernoulli{piδ(X)},
where logit{piδ(X)} = −(5.5, 1, 1)X. By this design, the RT selection rate is around 0.4%, which
results in a roughly n ≈ 1000 subjects in the RT sample. The treatment assignment in the RT
sample is A ∼ Bernoulli(0.5).
For the population, we take a random sample of size m = 5000 to form a RW sample. For
patients in the RW sample, the treatment assignment is A | X, δ = 0 ∼ Bernoulli{eA(X)}, where
we consider both linear and nonlinear propensity score models:
PSM I: logit{eA(X)} = (1,−2,−2)X,
PSM II: logit{eA(X)} = (1, 1,−1, 1,−1)Z.
The actual observed outcome Y in both samples is generated by Y = AY (1) + (1−A)Y (0).
To assess the robustness against parametric model assumptions for the proposed estimator,
we use generalized linear models with X for fitting models. When the true generative models use
the nonlinear transformation of X, the fitted parametric models are misspecified. We compare
the following four model specification scenarios:
• Scenario 1 (OM I /PSM I): both outcome and propensity score generative models use linear
predictors X;
• Scenario 2 (OM I/PSM II): the outcome generative model model uses linear predictors X;
the propensity score generative model uses nonlinear predictors X;
• Scenario 3 (OM II/PSM I): the outcome generative model uses nonlinear predictors X; the
propensity score generative model uses linear predictors X;
• Scenario 4 (OM II/PSM II): both outcome model and propensity score models use nonlinear
predictors X.
We compare the following estimators for the HTE:
1. covj.rt ψ̂covj.rt: the covariate adjustment approach of Tian et al. (2014) that fits Yi against
the adjusted covariate (Ai − 0.5)Xi using the generalized linear model based on the RT
data;
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2. opt.ee ψ̂opt.ee: the integrative estimator solving the optimal estimating equation (7) applied
to the combined RT and RW data, where the propensity score model is a logistic regression
model with linear predictors X and the outcome mean model is a linear regression model
for the continuous outcome and a logistic regression model for the binary outcome, both
with linear predictors X.
3. opt.ee(ml) ψ̂opt.ee(ml): the integrative estimator solving the optimal estimating equation (7)
applied to the combined RT and RW data, where the propensity score model is a logistic
sieve model with the power series X, X2 and their two-way interactions, and the outcome
mean model is a linear sieve model for the continuous outcome and a logistic sieve model
for the binary outcome, both the power series X, X2 and their two-way interactions.
4. elast ψ̂: the proposed elastic integrative estimator solving (12) with c = χ2p,0.90 and  = 1, 2.
We consider the replication weighting approach for estimating the variances of ψ̂covj.rt, ψ̂opt.ee
and ψ̂opt.ee(ml). For the proposed elastic estimator ψ̂, we use the replication weighting approach
for estimating Σ̂SS with replication samples 50. We consider the percentile bootstrap CI for ψ̂
with the number of bootstrap samples 50.
All simulations are all based on 500 Monte Carlo replications. Figure 1 summarizes the
results for the continuous outcome and the binary outcome. Although the covariate adjustment
estimator ψ̂covj.rt is unbiased across different scenarios, its variability is large. The optimal
estimating equation estimator ψ̂opt.ee gains efficiency over ψ̂covj.rt by leveraging the large sample
size of the RW data and is doubly robust in the sense that it has small biases if either the outcome
model is correctly specified as in Scenario (S2) or the propensity score model is correctly specified
as in Scenario (S3). However, when both the outcome model and the propensity score model
are misspecified as in Scenario (S4), it has large biases. The double machine learning estimator
ψ̂opt.ee(ml) is efficient and robust to model misspecification by using the flexible models for the
outcome model and the propensity score model. The elastic integrative estimator ψ̂ has small
biases across the four scenarios. Compared to ψ̂covj.rt, ψ̂ has smaller variances by integrating
the RW data; compared to ψ̂opt.ee and ψ̂opt.ee(ml), ψ̂ has larger variances by the possibility of
rejecting the RW data for an integrative analysis. However, as we show later that the inclusion
of the test protects against the assumption violation. Moreover, ψ̂ has a similar performance
for  = 1 and  = 2. In the supplementary material, the additional simulation results show
that ψ̂ is also robust to the choice of cγ . Table 1 reports the numerical results on the bias and
variance of point estimators and the coverage rate of 95% CI. By using the smooth technique
in the proposed elastic integrative estimator, the percentile bootstrap provides a good coverage
property.
14
Figure 1: Boxplot of the HTE estimators for the continuous outcome (the top four panels) and
the binary outcome (the bottom four panels) under four model specification scenarios (S1)–(S4).
"OM-c I/PSM I" means the outcome generative model is OM I for the continuous outcome and the propensity score
generating mode is PSM I. Similar meanings apply to others. The estimators are "covj.rt": the covariate adjustment
estimator of Tian et al. (2014) applied to the RT data, "opt.ee": the optimal estimating equation approach applied to
the combined RT and RW data with parametric models for the nuisance functions, "opt.ee(ml)": the optimal estimating
equation approach applied to the combined RT and RW data with machine learning methods (the method of sieves) for
the nuisance functions, "elas 1": the proposed elastic integrative estimator with  = 1, and "elas 2": the proposed elastic
integrative estimator with  = 2. The solid line indicates the true parameter value. The labels 1, 2, 3 index the parameters
ψ0,1, ψ0,2, ψ0,3 in the vector ψ0.
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Table 1: Simulation results for the continuous outcome and the binary outcome under four model
specification scenarios (S1)–(S4): bias of point estimates, Monte Carlo variance, and the coverage
rate of 95% confidence interval.
Continuous covj.rt opt.ee opt.ee(ml) elas 1 ( = 1) elas 2 ( = 2)
Outcome ψ0,1 ψ0,2 ψ0,3 ψ0,1 ψ0,2 ψ0,3 ψ0,1 ψ0,2 ψ0,3 ψ0,1 ψ0,2 ψ0,3 ψ0,1 ψ0,2 ψ0,3
Bias ×104
1. OM I/PSM I -25 62 31 -16 -6 4 -17 -9 4 -40 -6 -14 -37 -6 -13
2. OM I/PSM II -25 62 31 -7 -4 -0 -13 -6 4 -44 -20 -5 -46 -21 -6
3. OM II/PSM I -109 -168 -64 -4 8 12 -6 2 -12 5 3 -3 -0 -1 -4
4. OM II/PSM II -109 -168 -64 3579 1276 -230 -9 3 -16 2 7 -16 -5 3 -16
Monte Carlo variance ×104
1. OM I/PSM I 832 626 568 11 13 11 11 13 11 50 22 21 45 21 20
2. OM I/PSM II 832 626 568 9 10 13 11 10 13 48 19 22 46 18 21
3. OM II/PSM I 906 456 581 9 16 13 7 6 6 23 9 13 22 9 12
4. OM II/PSM II 906 456 581 7 12 15 4 4 5 21 8 11 19 8 10
95% Wald CI coverage rate
1. OM I/PSM I 94.0 94.2 93.6 95.6 93.0 94.4 95.4 92.6 95.0 94.8 93.4 93.4 96.8 94.0 93.4
2. OM I/PSM II 94.0 94.2 93.6 94.6 95.8 93.0 94.6 95.8 92.4 94.4 94.6 93.8 95.6 95.4 936
3. OM II/PSM I 94.4 94.2 94.6 95.6 95.0 95.4 95.4 95.4 94.0 94.0 94.6 92.2 95.6 95.2 93.4
4. OM II/PSM II 94.4 94.2 94.6 0 6.0 92.8 94.2 94.2 95.2 95.2 96.4 93.2 97.2 97.0 93.6
Binary covj.rt opt.ee opt.ee(ml) elas 1 ( = 1) elas 2 ( = 2)
outcome ψ0,1 ψ0,2 ψ0,3 ψ0,1 ψ0,2 ψ0,3 ψ0,1 ψ0,2 ψ0,3 ψ0,1 ψ0,2 ψ0,3 ψ0,1 ψ0,2 ψ0,3
Bias ×104
1. OM I/PSM I -50 -6 -10 21 10 17 34 46 57 58 52 73 54 52 69
2. OM I/PSM II -50 -6 -10 31 9 3 51 60 48 75 81 58 69 78 52
3. OM II/PSM I 71 33 20 14 10 -2 13 57 54 65 67 78 65 66 76
4. OM II/PSM II 71 33 20 -226 -164 194 12 52 63 62 67 84 65 63 84
Monte Carlo variance ×104
1. OM I/PSM I 157 60 57 14 16 15 14 16 16 54 30 27 52 29 26
2. OM I/PSM II 157 60 57 10 12 14 12 13 14 55 28 26 53 26 25
3. OM II/PSM I 123 52 48 12 14 14 13 16 17 27 22 22 26 22 22
4. OM II/PSM II 123 52 48 10 12 14 12 13 15 26 19 21 24 18 21
95% Wald CI coverage rate
1. OM I/PSM I 91.4 93.6 93.4 95.6 93.8 92.0 95.6 95.0 94.2 95.2 92.8 94.0 95.4 93.4 94.2
2. OM I/PSM II 91.4 93.6 93.4 95.8 95.2 96.0 95.0 96.8 96.4 94.4 93.6 93.2 94.8 94.2 93.8
3. OM II/PSM I 97.0 95.0 95.0 95.8 94.4 95.0 96.2 96.6 96.8 96.2 96.4 97.2 96.8 96.8 96.8
4. OM II/PSM II 97.0 95.0 95.0 91.0 93.2 92.6 95.6 97.0 97.8 97.2 95.6 97.2 97.2 96.4 97.0
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5.2 Robustness to the violation of Assumption 1 in RW
To assess the robustness against assumption violation for the RW data, we consider scenarios
with OM I and PSM I where the true data generative model use linear predictors X, but we may
omit confounders when fitting the models. We compare the following four scenarios:
• Scenario (S5) (OM I /PSM I): we consider adjusting for X in both outcome and propensity
score models;
• Scenario (S6) (OM I/PSM I): we consider adjusting only for X1 in the outcome model and
adjusting for X in the propensity score model;
• Scenario (S7) (OM I/PSM I): we consider adjusting for X in the outcome model and
adjusting only for X1 in the propensity score model;
• Scenario (S8) (OM I/PSM I): we consider adjusting only for X1 in both outcome and
propensity score models, which essentially assumes Y (0) ⊥ A | (X1, δ = 0) violating As-
sumption 1 (ii) for the RW data.
All simulations are all based on 500 Monte Carlo replications. Figure 2 summarizes the results for
the continuous outcome and the binary outcome. Under Scenarios (S5)–(S7), if at least one of the
outcome and propensity score models uses the true set of confounders X, all estimators ψ̂covj.rt,
ψ̂opt.ee, ψ̂opt.ee(ml) and ψ̂elas have small biases. However, under Scenario (S8) when Assumption
1 (ii) is violated for the RW data, ψ̂opt.ee and ψ̂opt.ee(ml) have large biases, but ψ̂elas have smaller
biases by the protection of the violation test designed in the estimator.
6 APPLICATION
We apply the proposed estimators to evaluate the effect of adjuvant chemotherapy for early-stage
resected non-small cell lung cancer (NSCLC) using the CALGB 9633 data and a large clinical
oncology database, the NCDB. In CALGB 9633, we include 319 patients with 163 randomly
assigned to observation (A = 0) and 156 randomly assigned to chemotherapy (A = 1). The
comparable sample from the NCDB includes 15337 patients diagnosed with NSCLC between
years 2004 – 2016 in stage IB disease with 11021 on observation and 4316 received chemotherapy
after surgery. The numbers of treated and controls are relatively balanced in the CALGB 9633
trial while they are unbalanced in the NCDB. We include four covariates in the analysis: gender
(1 = male, 0 = female), age, indicator for histology (1 = squamous, 0 = non-squamous), and
tumor size in cm. The outcome is the indicator of cancer recurrence within 3 years after the
surgery, i.e. Y = 1 if recurrence occurred and Y = 0 otherwise.
Table 3 reports the covariate means by treatment group in the two samples. Due to treatment
randomization, covariates are balanced between the treated and the control in the CALGB 9633
trial sample. While due to lack of treatment randomization, covariates are highly unbalanced
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Figure 2: Boxplot of the HTE estimators for the continuous outcome (the top four panels) and
the binary outcome (the bottom four panels) under four model specification scenarios (S5)–(S8).
"OM-c I/PSM I" means the outcome generative model is OM I for the continuous outcome and the propensity score
generating mode is PSM I. Similar meanings apply to others. The estimators are "covj.rt": the covariate adjustment
estimator of Tian et al. (2014) applied to the RT data, "opt.ee": the optimal estimating equation approach applied to
the combined RT and RW data with parametric models for the nuisance functions, "opt.ee(ml)": the optimal estimating
equation approach applied to the combined RT and RW data with machine learning methods (the method of sieves) for
the nuisance functions, "elas 1": the proposed elastic integrative estimator with  = 1, and "elas 2": the proposed elastic
integrative estimator with  = 2. The solid line indicates the true parameter value. The labels 1, 2, 3 index the parameters
ψ0,1, ψ0,2, ψ0,3 in the vector ψ0.
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Table 2: Simulation results for the continuous outcome and the binary outcome under four model
specification scenarios (S5)–(S8): bias of point estimates, Monte Carlo variance, and the coverage
rate of 95% confidence interval.
Continuous covj.rt opt.ee opt.ee(ml) elas 1 ( = 1) elas 2 ( = 2)
Outcome ψ0,1 ψ0,2 ψ0,3 ψ0,1 ψ0,2 ψ0,3 ψ0,1 ψ0,2 ψ0,3 ψ0,1 ψ0,2 ψ0,3 ψ0,1 ψ0,2 ψ0,3
Bias ×104
1. OM I/PSM I -25 62 31 -35 12 -19 -35 10 -19 -30 -2 -7 -32 -2 -8
2. OM I/PSM II -25 62 31 -38 8 -25 -28 2 -3 -42 -16 -1 -36 -12 -0
3. OM II/PSM I -25 62 31 -26 23 -16 -19 -1 8 12 3 38 6 -0 34
4. OM II/PSM II -25 62 31 6592 1074 1349 6588 1083 1352 -33 -12 -7 -33 -12 -7
Monte Carlo variance ×104
1. OM I/PSM I 832 626 568 11 10 12 11 10 12 51 19 21 47 18 21
2. OM I/PSM II 832 626 568 11 9 9 12 12 16 52 21 24 48 19 23
3. OM II/PSM I 832 626 568 15 18 30 14 13 21 100 31 67 90 30 65
4. OM II/PSM II 832 626 568 14 17 20 14 17 20 328 78 166 328 78 166
95% Wald CI coverage rate
1. OM I/PSM I 94.0 94.2 93.6 94.0 93.0 93.2 94.4 93.4 93.6 96.8 95.8 96.4 97.8 96.8 97.2
2. OM I/PSM II 94.0 94.2 93.6 94.8 93.6 94.4 94.6 93.4 93.4 95.6 94.6 93.2 97.4 95.2 94.8
3. OM II/PSM I 94.0 94.2 93.6 94.0 94.8 94.0 93.6 95.2 93.4 97.8 98.6 96.0 98.8 98.6 96.8
4. OM II/PSM II 94.0 94.2 93.6 0 24.0 17.4 0 23.2 18.0 92.4 95.2 92.4 92.2 95.2 92.4
Binary covj.rt opt.ee opt.ee(ml) elas 1 ( = 1) elas 2 ( = 2)
Outcome ψ0,1 ψ0,2 ψ0,3 ψ0,1 ψ0,2 ψ0,3 ψ0,1 ψ0,2 ψ0,3 ψ0,1 ψ0,2 ψ0,3 ψ0,1 ψ0,2 ψ0,3
Bias ×104
1. OM I/PSM I -55 16 -9 9 42 15 30 73 60 80 88 104 76 86 99
2. OM I/PSM II -55 16 -9 14 25 10 30 54 62 110 79 120 103 76 114
3. OM II/PSM I -50 -6 -10 7 24 14 4 48 5 12 48 25 5 43 20
4. OM II/PSM II -50 -6 -10 -1547 -508 -80 -1550 -484 -91 -421 -92 -30 -435 -100 -29
Monte Carlo variance ×104
1. OM I/PSM I 158 61 57 15 18 16 16 19 17 52 29 26 52 29 26
2. OM I/PSM II 158 61 57 15 17 13 18 20 23 52 30 32 51 29 31
3. OM II/PSM I 157 60 57 17 19 18 17 20 18 55 30 28 54 30 27
4. OM II/PSM II 157 60 57 13 18 17 13 19 17 170 53 43 158 50 41
95% Wald CI coverage rate
1. OM I/PSM I 91.3 93.4 93.6 95.7 93.8 93.4 95.7 95.2 95.7 97.0 95.4 95.9 97.0 96.4 95.9
2. OM I/PSM II 91.3 93.4 93.6 94.9 94.0 94.0 94.2 94.7 93.8 96.0 94.9 93.2 96.6 96.0 93.2
3. OM II/PSM I 91.4 93.6 93.4 94.0 94.2 93.8 93.8 94.0 94.0 97.0 95.0 96.8 97.8 95.8 97.6
4. OM II/PSM II 91.4 93.6 93.4 1.6 74.6 91.2 1.6 79.2 91.0 88.2 94.6 95.4 86.8 94.0 95.8
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Table 3: Covariate means by treatment group in the CALGB 9633 trial sample and the NCDB
sample.
A Gender Age Histology Tumor size
RT: CALGB 9633 A = 1 64.1% 60.57 40.4% 4.62
A = 0 63.8% 61.08 39.3% 4.57
RW: NCDB A = 1 54.2% 63.93 35.5% 5.19
A = 0 54.8% 69.42 40.4% 4.68
Table 4: Point estimate, standard error and 95% Wald confidence interval of the causal risk
difference between adjuvant chemotherapy and observation based on the CALGB 9633 trial
sample and the NCDB sample.
Intercept (ψ0,1) Age (ψ0,2) Tumor Size (ψ0,3)
Est. S.E. C.I. Est.×102 S.E.×102 C.I. ×102 Est.×102 S.E.×102 C.I. ×102
covj.rt -1.07 0.77 (-2.58, 0.43) 1.61 1.18 (-0.71, 3.93) -0.96 5.45 (-11.65, 9.72)
opt.ee 0.27 0.13 (0.01, 0.54) -0.74 0.19 (-1.12, -0.37) 1.57 1.69 (-1.75, 4.89)
opt.ee(ml) 0.42 0.17 (0.07, 0.77) -0.62 0.20 (-1.00, -0.24) -3.23 3.04 (-9.20, 2.73)
elas -0.65 - (-3.38, 4.35) 0.49 - (-4.96, 4.42) 5.78 - (-24.98, 40.75)
in the NCDB sample. It can be seen that older patients with histology and smaller tumor size
are likely to choose a conservative treatment, on observation. Moreover, we can not rule out the
possibility of unmeasured confounders in the NCDB sample.
We assume the HTE function in Example 2 with age and tumor size as the treatment effect
modifiers. We compare the same set of estimators and variance estimators considered in the
simulation study. Table 4 reports the results. Due to the limited sample size of the trial sample,
all components in ψ̂covj.rt are not significant. By directly combining the trial sample and the
NCDB sample, both ψ̂opt.ee and ψ̂opt.ee(ml) reveal that age is a significant treatment effect modifier
and that older patients benefit less from the chemotherapy compared to younger patients. But
this finding may be subject to unmeasured confounding biases of the NCDB sample. In the
proposed elastic analysis, the test statistic is T = 679, a strong evidence that the NCDB sample
does not meet the required assumptions for combining. This evidence is reflected in the inflated
standard error of the elastic integrative estimator ψ̂elas. Therefore, naively combining RT and
RW samples may lead to biased conclusions, and careful evaluation of the quality of the RW
data as in the elastic integrative approach is critical to safeguard unbiasedness.
7 CONCLUDING REMARKS
The proposed elastic estimator integrates “high-quality small data” with “big data” to simultane-
ously leverage small but carefully controlled unbiased experiments and massive, information-rich
RW datasets for HTEs. Our method is likely to lead a step forward toward actualizing the full
benefit of vast RW databases in precision medicine research and beyond.
The proposed estimator is non-regular and belongs to pre-test estimation by construction
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(Giles and Giles, 1993). Exact inference for pre-test estimation is difficult because of introducing
a random process from the test. This issue cannot be solved by sampling splitting that divides
the sample into two parts for testing and estimation, separately (Toyoda and Wallace, 1979).
This is because sample splitting cannot bypass the issue of the additional randomness due to pre-
testing and therefore the pre-testing impact still remains. Many authors have considered exact
inference for pre-test estimators in regression models; see, e.g., Bancroft (1944) and Giles and
Srivastava (1992). In the future, we will investigate exact inference for our proposed estimators.
We have assumed that the treatment effect function is correctly specified. In future work,
we will derive tests based on over-identification restrictions tests (Yang and Lok, 2016) for eval-
uating a treatment effect model. Moreover, to evaluate the treatment effect modifications of
adjuvant chemotherapy, the set of treatment effect modifiers are suggested based on subject
matter knowledge. Without such knowledge, it is important to identify the true treatment effect
modifiers among a set of variables. We will develop a variable selection procedure for identifying
effect modifiers. The insight is that we can create a larger number of estimating functions than
the number of parameters. The problem for effect modifiers selection falls into the recent work
of Chang et al. (2018) on high-dimensional statistical inferences with over-identification.
The current framework allows the outcome to be continuous or binary. In cancer clinical trials,
survival outcomes are most common. Following Yang (2018), we will consider the structural
failure time model for the HTE that specifies the relationship of the potential baseline failure
time T (0) and the actual observed failure time T . We assume that, given any X, T (0) ∼
T exp{Aτψ0(X)}, where ∼ means “has the same distribution as.” This model entails that the
treatment effect is to accelerate or decelerate the failure time compared to the baseline failure
time T (0). Intuitively, exp{Aτψ0(X)} describes the relative increase/decrease in the failure time
had the patient received treatment compared to had the treatment always been withheld and the
effect rate of the treatment can possibly be modified by τψ0(X). Then, we define Hψ in (2) as
Hψ = T exp{Aτψ(X)} to mimic the baseline failure time T (0). A unique challenge in the survival
outcome setting is the possibility of censoring which prevents observing all T ’s. In our future
work, we will develop elastic algorithms to combine the RT and RW data for right-censored
survival outcome.
Because the RW data were not collected for research purposes, data quality may be poor such
as measurement errors and missingness. Moreover, data collected from RTs may not be avail-
able in RW data or vice versa, resulting in data structure misalignment. Developing principled
methods to deal with these practical issues will be our future work.
SUPPLEMENTARY MATERIAL
Supplementary material online includes technical details, proofs and additional simulation.
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